RISPERDAL viser ikke en klinisk relevant effekt på lithiums, valproats, digoxins eller topiramats farmakokinetik.
RISPERDAL does not show a clinically relevant effect on the pharmacokinetics of lithium, valproate, digoxin or topiramate.